Along with its Q4 2024 financials on Thursday, antiviral developer Arbutus Biopharma (NASDAQ:ABUS) announced plans to reduce its workforce by 57% as part of a broader restructuring program ...

A lot has happened since I last put Arbutus Biopharma Corporation (NASDAQ:ABUS) in the spotlight early last summer. This clinical stage biopharma concern. Arbutus laid off approximately 40% of its ...

WARMINSTER, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage ...